Almarri Firas K, Algahtani Saad, Alokby Ghassan, Alanazi Muteb, Alsaleh Saad
Department of Otorhinolaryngology-Head and Neck Surgery, Ad Diriyah Hospital, Riyadh Third Health Cluster, Ministry of Health, Riyadh, Saudi Arabia.
College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia.
Am J Rhinol Allergy. 2025 Jan;39(1):49-57. doi: 10.1177/19458924241287959. Epub 2024 Oct 7.
Chronic rhinosinusitis with nasal polyps (CRSwNP) remains challenging to manage effectively, with high symptom recurrence rates and significant impacts on quality of life, prompting a need to evaluate the real-world use of biologics and optimize treatment strategies.
To assess the real-world application and perspectives of American Rhinologic Society (ARS) members on biologic treatments and surgical interventions for CRSwNP, focusing on clinical practice patterns, adoption of biologics, and their impact on surgical practices.
A standardized questionnaire evaluated clinical practice patterns of biologics prescriptions and surgery in treating CRSwNP between July 2022 and August 2023. Data collected from 162 ARS members were analyzed.
Of 162 participants, a substantial majority (95.06%, = 154) reported prescribing biologics in their practice. Notably, 45.45% (= 70) found biologics easily accessible, although accessibility challenges remained for some. The impact of biologics on surgical practices was significant, with 36.36% (= 56) observing a marked reduction in revision sinus surgeries. Among the participants, 47.16% (= 71) agreed that aspirin-exacerbated respiratory disease (AERD) was the highest phenotype that tended to increase the possibility of biological treatment by more than 20%. Adopting Patient-Reported Outcome Measures (PROMs) was prevalent, with 57.79% (= 89) utilizing them in patient management.
The study highlights the evolving landscape in managing CRSwNP, with a marked trend toward integrating biological treatments into clinical practice. It underscores the necessity for continued research, updates to clinical guidelines, and enhanced practitioner education to optimize treatment outcomes for CRSwNP patients.
伴有鼻息肉的慢性鼻-鼻窦炎（CRSwNP）的有效管理仍然具有挑战性，症状复发率高，对生活质量有重大影响，这促使人们需要评估生物制剂在现实世界中的应用情况并优化治疗策略。
评估美国鼻科学会（ARS）成员对CRSwNP生物治疗和手术干预的现实世界应用及看法，重点关注临床实践模式、生物制剂的采用情况及其对手术实践的影响。
采用标准化问卷评估2022年7月至2023年8月期间生物制剂处方和手术在治疗CRSwNP方面的临床实践模式。对从162名ARS成员收集的数据进行分析。
在162名参与者中，绝大多数（95.06%，n = 154）报告在其临床实践中开具生物制剂处方。值得注意的是，45.45%（n = 70）的人认为生物制剂易于获取，尽管对一些人来说获取仍存在挑战。生物制剂对手术实践的影响显著，36.36%（n = 56）的人观察到鼻窦翻修手术明显减少。在参与者中，47.16%（n = 71）同意阿司匹林加重的呼吸系统疾病（AERD）是最有可能使生物治疗可能性增加超过20%的最高表型。采用患者报告结局测量（PROMs）很普遍，57.79%（n = 89）的人在患者管理中使用它们。
该研究突出了CRSwNP管理中不断变化的情况，有将生物治疗纳入临床实践的明显趋势。它强调了持续研究、更新临床指南以及加强从业者教育以优化CRSwNP患者治疗结果的必要性。
